38 results about "Therapy related" patented technology

A method of treating a metabolic condition in a patient, comprising:

• • determining a target non-immediate effect of a therapy relating to treatment of a metabolic condition; and
  • applying an electric field to an abdominal cavity of the patient in a manner designed to at least approach said target.

The invention relates to remote controlled blood cleaning of a patient (P). A dialysis unit (110) treats the patient's (P) blood in accordance with a prescribed therapy. The dialysis unit (110) has a bi-directional wireless interface (110W-120W) towards a gateway unit (120), which is further connected (125) to a remote host (140) via at least one interconnecting network (130). Thus, therapy related parameters (D_bp, D_r, d_h, D_w) can be transmitted from the dialysis unit (110) to the remote host (140). It is also rendered possible for the remote host (140) to transmit control data (D_ctr1) to the dialysis unit (110), the control data (D_ctr1) influencing the prescribed therapy being, or to be, executed by the dialysis unit (1 10).

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

A method of treating a metabolic condition in a patient, comprising:

• • determining a target non-immediate effect of a therapy relating to treatment of a metabolic condition; and
  • applying an electric field to an abdominal cavity of the patient in a manner designed to at least approach said target.

The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

The invention belongs to the technical field of medical imaging, and specifically relates to a tumor-targeting polypeptide probe and application of the probe in tumor imaging. The invention relates to the tumor-targeting polypeptide probe. The general formula of the polypeptide probe is R-X-YW7, the YW7 is a polypeptide specifically targeting ANXA2 in vivo, and the sequence is YWRGVYN; and X is a linker, R is a signal unit, and X and R are covalently connected. The polypeptide probe is applied to preparation of a tumor diagnosis reagent, a tumor imaging reagent, a tumor operation guiding agent and/or a tumor active targeted therapy related drug tracer. Experiments prove that the tumor-targeting polypeptide probe provided by the invention has strong specificity and high sensitivity, and through a nude mouse subcutaneous pancreatic cancer model, a nude mouse subcutaneous glioma model and a nude mouse in-situ glioma model which are cultured in sequence, the polypeptide probe can be specifically absorbed by glioma, and quickly accumulates in tumor cells or tumor tissues within 2 hours; and compared with a control group, the tumor-targeting polypeptide has a remarkable tumor targeting advantage, and is clinically used for tumor diagnosis and treatment.

The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.

The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

The present invention relates to regulation of the cell cycle. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

The objective of the present invention is to provide a psychotherapy device with which it is possible for hidden negative feelings and automatic thoughts of which a subject is unaware to be understoodwith a high degree of accuracy, without placing a burden on the subject, and which can be implemented automatically with respect to therapies for alleviating or coping with problems of stress, or forpromoting awareness and self development aimed at problem solving. This psychotherapy device is provided with: a solution means for implementing a therapy relating to the main complaint of a subject;and a result display means for displaying the effect of psychotherapy conducted using the solution means. The solution means extracts, as sensory image information, at least one of, a scene and a memory of an unpleasant situation brought to mind on the basis of the main complaint of the subject, and an unpleasant feeling and physical discomfort caused by the scene or memory, and then implements atherapy employing images, in accordance with the extracted sensory image information.

The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. For example, the present invention is directed to genes encoding components of the mitochondrial respiratory chain and genes encoding glycolysis enzymes, which are involved in lifespan regulation, and genes and gene products in pathways controlled by such genes. Other genes and gene products identified as regulating aging and aging pathways include a gene encoding a GTPase; a transcriptional activator; novel genes: llw-1, llw-2, llw-3, and llw-4; genes encoding cytochrome P450 proteins (involved in steroid biosynthesis); a melatonin synthesis gene; genes encoding insulin and insulin-like peptides; genes encoding heat shock factors; genes encoding catalases; stress-response genes; and metabolic genes. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, antisense nucleic acids, and ribozymes, that regulate, e.g., enhance, adult lifespan via modulation of aging associated proteins; as well as to the use of expression profiles, markers, and compositions in diagnosis and therapy related to lifespan extension, life expectancy, and aging. The present invention also relates to gene therapy involving lifespan associated genes.

The present invention pertains to a device and corresponding method for determining information relating to the treatment of a patient, preferably relating to a patient having a respiratory disorder. The device comprises a fluid channel configured to be in fluid communication with a medical gas source at a first end and with a patient interface at a second end, a sensor arrangement having at least a first sensor for measuring a value of a first flow parameter in the channel and a second sensor for measuring a value of a second flow parameter in the channel, wherein the first sensor and the second sensor are spaced apart from each other along a longitudinal axis of the channel, and a control unit in communication with the first sensor and the second sensor. The control unit determines flow direction of a medical gas in the channel based on sensor measurements.